Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Immuneering (IMRX) EBIT Margin (2020 - 2022)

Immuneering's EBIT Margin history spans 3 years, with the latest figure at 3073627.91% for Q4 2022.

  • On a quarterly basis, EBIT Margin fell 306776489.0% to 3073627.91% in Q4 2022 year-over-year; TTM through Sep 2023 was 12328770.77%, a 1231911324.0% decrease, with the full-year FY2022 number at 16325.77%, down 1469661.0% from a year prior.
  • EBIT Margin came in at 3073627.91% for Q4 2022, down from 34362.04% in the prior quarter.
  • The five-year high for EBIT Margin was 644.66% in Q3 2020, with the low at 3073627.91% in Q4 2022.
  • Historically, EBIT Margin has averaged 285392.02% across 3 years, with a median of 1772.01% in 2021.
  • Biggest five-year swings in EBIT Margin: plummeted -46060bps in 2021 and later crashed -306776489bps in 2022.
  • Year by year, EBIT Margin stood at 877.56% in 2020, then tumbled by -568bps to 5863.02% in 2021, then tumbled by -52324bps to 3073627.91% in 2022.
  • Business Quant data shows EBIT Margin for IMRX at 3073627.91% in Q4 2022, 34362.04% in Q3 2022, and 12334.43% in Q2 2022.